Anaesthesin

Quick links to important sections

Anaesthesin

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anaesthesin

Anaesthesin is a medication primarily known for preparations containing the active ingredient Benzocaine, which functions to produce localized surface numbing. It is used to provide temporary relief from minor, acute discomfort directly at the site of application.


Property Description
Active ingredient Benzocaine (Ethyl Aminobenzoate)
Form Topical (Solutions, Gels, Ointments, Sprays, Lozenges)
Pharmacological class Local Anesthetic (Amino Ester Class)
Common use Localized, symptomatic relief of minor pain and itching
Origin Synthetic (ester derivative of p-Aminobenzoic acid)

What Type of Medicine is Anaesthesin (Benzocaine)?

Anaesthesin is classified as a Local Anesthetic, belonging to the Amino Ester chemical class. Its core component, Benzocaine, is a synthetic compound derived from p-Aminobenzoic acid, which offers a targeted numbing effect distinct from systemic pain relievers. The compound's recognized mechanism involves inhibiting voltage-gated sodium channels on the nerve endings, preventing the transmission of nerve impulses to the central nervous system.

This anesthetic property is clinically recognized for providing effective surface anesthesia. The medication is typically positioned as an Over-The-Counter (OTC) option, offering accessible and localized relief that does not affect general consciousness.

Forms and General Purpose of Anaesthesin

Anaesthesin is formulated exclusively for the topical route of administration, available in various dosage forms such as solutions, ointments, sprays, and lozenges, which ensures its action is confined to the surface. Its overall purpose is to furnish rapid symptomatic relief by inducing localized numbness.

As a topically applied agent, Benzocaine is employed to reduce or relieve painful stimuli stemming from minor irritations on the skin or mucosal surfaces, such as a mild mouth or throat irritation. The rapid onset of localized numbing is a key feature often highlighted in its use for acute, surface-level discomfort.

Regulatory References

  1. Benzocaine DailyMed Label

What side effects are possible with Anaesthesin?

Possible side effects and safety information

Anaesthesin (Benzocaine) is associated with adverse reactions that are classified based on the affected organ systems and frequency, as documented in official government regulatory labels.

Localized effects at the application site are generally the most common occurrences. These effects are classified under Skin and Subcutaneous Tissue Disorders and typically involve sensations such as burning, stinging, or tingling. Official labeling also documents the possibility of Contact Dermatitis or other forms of localized irritation.

Serious Adverse Reactions and Systemic Safety

The principal systemic safety concern highlighted by regulatory agencies is Methemoglobinemia, a rare but serious adverse reaction classified under Blood and Lymphatic System Disorders. This condition impairs the blood's ability to carry oxygen and may be characterized by symptoms such as gray, pale, or blue-colored skin (cyanosis), shortness of breath, headache, and fatigue. The onset of these symptoms is typically documented to occur within minutes to one or two hours after application and can manifest after the first use or subsequent uses.

Population-Specific Safety Considerations

The risk of developing Methemoglobinemia is explicitly documented as being higher in certain groups. Regulatory agencies advise against the use of Benzocaine in infants and children under two years of age due to this heightened, life-threatening risk. Older adults and individuals with underlying conditions such as heart disease or breathing problems are also noted as potentially being at greater risk for complications from this reaction.

Furthermore, official safety notes indicate that the risk of systemic absorption and associated serious adverse reactions increases when the medication is applied to large surface areas, used on broken or significantly irritated skin, or applied with occlusive dressings.

Overdose and Emergency Response

The official regulatory profile for Anaesthesin (Benzocaine) overdose is defined by the serious systemic condition, methemoglobinemia. This life-threatening condition impairs the blood’s capacity to transport oxygen effectively, a risk documented even after use consistent with product instructions.

Documented Manifestations of Overdose

Symptoms documented in regulatory labeling require immediate medical evaluation as they may indicate a severe reduction in blood oxygen levels:

  • Skin Discoloration: Pale, gray, or blue-colored skin, lips, or nail beds (cyanosis).
  • Respiratory/Cardiac Signs: Shortness of breath, rapid heart rate (tachycardia), and fatigue.
  • Neurological Signs: Headache, dizziness, and confusion.

Required Emergency Action

Immediate medical attention is necessary if any of the signs of methemoglobinemia occur. Regulators mandate that individuals should seek immediate medical attention and contact a Poison Control Center right away. The symptoms can develop rapidly, typically within minutes to two hours following application.

Management and Risk Considerations

The documented intervention for moderate-to-severe methemoglobinemia is the administration of Methylene Blue. Supportive treatment, including supplemental oxygen, is also required. Official labeling notes that certain populations are at increased risk for severe outcomes, including infants younger than 2 years of age and patients with pre-existing breathing problems or heart disease. Standard pulse oximeters may provide inaccurate readings, and specialized hospital monitoring may be required.

Therapeutic Uses of Anaesthesin

What Anaesthesin Treats: Main Uses and Benefits

Anaesthesin (Benzocaine) is applied across therapeutic domains where short-term symptomatic assistance is needed to manage localized discomfort in accessible surface areas. This medication is generally used to provide localized numbing for short-term symptomatic support in clinical settings that involve acute or unstable symptom patterns, and contributes to easing the overall symptom load.


The medication is commonly used to help manage symptoms related to inflammatory or irritative states on mucosal and epidermal surfaces, such as pain, burning, and itching associated with minor skin trauma (like first-degree sunburn, minor cuts, and scrapes) or specific localized irritations. For instance, its application is relevant for easing oral discomfort arising from canker sores, temporary denture irritation, gum soreness, and general throat irritation. This application is considered relevant when symptoms interfere with daily comfort.

“The symptomatic relief provided by localized numbing may assist with symptom management when acute manifestations interfere with function.”

Quick Fact: Relief for Acute Localized Discomfort

Anaesthesin plays a role in managing episodes characterized by localized physical discomfort, not systemic pain, and offers symptomatic relief that helps patients cope more steadily with symptom fluctuations at the surface level.

Eligibility and Restrictions for Use

Eligibility Scope

Category Regulatory Status (Government Documentation)
Populations for whom use is allowed (as stated in label) Adults and children 2 years of age and older (for most topical and oral OTC products), subject to contraindications and warnings, typically for short-term use (FDA, NIH).
Populations for whom use is contraindicated Children younger than 2 years of age (absolute prohibition for OTC oral products due to methemoglobinemia risk) (FDA). Individuals with known hypersensitivity or allergy to Benzocaine or other ester-type local anesthetics (HPRA SmPC). Patients with a history of or suspected methemoglobinemia (HPRA SmPC).
Age-related eligibility rules Infants (<2 years): Use is contraindicated (FDA). Elderly Patients: Considered at greater risk for complications related to methemoglobinemia (FDA).
Condition-specific eligibility rules Use requires caution in patients with respiratory problems (e.g., asthma, emphysema), heart disease, anemia, or genetic enzyme defects (e.g., G6PD deficiency) due to heightened risk for methemoglobinemia complications (FDA, NIH).
Pregnancy and lactation eligibility status (if explicitly documented) Pregnancy: Classified as Category C (FDA); use is permitted only when the potential benefit justifies the potential risk (NIH). Lactation: Use is unlikely to affect the infant if applied away from the breast; must not be applied to the nipple area (NIH LactMed).
Eligibility-related restrictions The product must not be used on large areas of broken skin, open wounds, or in the presence of infections at the application site (NIH).

Resulting Eligibility Structure

Official eligibility statements:

  • The use of OTC oral Benzocaine products is contraindicated in children younger than 2 years of age (FDA).
  • The medicine is contraindicated in patients with a known hypersensitivity to Benzocaine or related anesthetics (HPRA SmPC).
  • Use in patients with respiratory or heart disease is restricted and requires caution due to a greater risk for complications related to methemoglobinemia (FDA, NIH).

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define who can and cannot use Anaesthesin by establishing absolute contraindications based on age (under 2 years) and known allergies. Eligibility for use in all other populations is conditioned by warnings concerning the heightened risk of a serious blood disorder in those with pre-existing conditions and the integrity of the application site, as stated in government labeling.

What should I know about interactions with other medicines?

Anaesthesin Interactions with other medicines and products

The interaction profile for Anaesthesin (Benzocaine) is defined by a chemical antagonism and a risk of additive pharmacodynamic effects, as documented in regulatory labeling.

Contraindicated Combinations

The co-administration of Benzocaine with Sulphonamide medicines is formally contraindicated. This prohibition exists because Benzocaine, a derivative of p-aminobenzoic acid (PABA), competitively inhibits the antibacterial actions of the Sulphonamides, resulting in therapeutic failure.

Pharmacodynamic Interaction Risk

A primary concern is the increased risk of methemoglobinemia when Benzocaine is used simultaneously with other Oxidizing Agents. This includes Nitrate and Nitrite Derivatives (such as Nitroglycerin or Isosorbide) and certain other agents, including Dapsone or Metoclopramide. This risk is classified as a serious pharmacodynamic interaction due to additive oxidizing effects.

Administration Constraints and Cautions

Interaction-related restrictions include a mandatory administration constraint for oral oromucosal preparations. Users must avoid drinking hot liquids while using the product, which is a required condition documented in labeling to maintain efficacy and prevent excessive absorption. Substances such as Hyaluronidase and the herbal product St. John's Wort are listed in regulatory documents as needing caution, with co-administration generally not recommended.

Mechanism of Action

Direct Inhibition of Voltage-Gated Sodium Channels ( Na v)

Anaesthesin (benzocaine) functions as a non-competitive inhibitor primarily targeting voltage-gated sodium channels ( Na v) within peripheral sensory neurons. The drug crosses the neural membrane in its uncharged form and binds directly within the channel pore, physically obstructing the necessary influx of sodium ions ( Na^+).

This physical obstruction prevents the electrical depolarization required for action potential propagation in afferent nerve fibers. The resulting failure of impulse generation leads to the localized cessation of sensory signal transmission from the application site, targeting both nociceptive and tactile impulses.

Mechanism Dependence on Tissue Environment

This mechanistic activity is highly dependent on the local tissue pH. In acidic environments, a smaller fraction of the drug remains uncharged, which limits its ability to penetrate the nerve cell membrane and reach the intracellular binding site. This constraint influences the degree of Na v channel blocking activity that can be achieved.

Dosage and Administration Information

Anaesthesin (Benzocaine) is exclusively administered via the topical route, encompassing application to the skin (cutaneous), the exterior rectal area, and mucous membranes of the mouth and throat (oromucosal). Its usage is standardized across multiple forms, including gels, solutions, sprays, and lozenges, with product strengths generally ranging from 5% to 20%.

The product is intended for as-needed (p.r.n.) use only, emphasizing intermittent application driven by the onset of localized discomfort. Administration is constrained by a maximum frequency; for most topical and oral solutions, this limit is three to four times daily. For lozenges, the schedule is restricted to one unit dissolved slowly, repeatable only every two hours.

Procedurally, the amount used should strictly cover the affected area without excess, and for oral application, the site may be recommended to be dried before use to aid adherence. Critical time-based constraints specify that the course of treatment must be short-term, typically limited to seven consecutive days or less. Furthermore, all oral formulations carry a high-level age restriction, specifying they are not intended for use in children under two years of age. Adherence to these strict dose and frequency ceilings is required.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Chronic Neuropathic Pain

Studies have examined the results of the drug for chronic neuropathic pain. Research evaluated whether the drug was associated with changes in pain scores. Clinical trials focused on changes in patient-reported pain intensity over a 12-week period.

Initial studies examined subject responses to the lowest dose. Further research explored the results across different doses across several patient groups.

Combination Therapy and Efficacy

Research explored whether the combination was associated with changes in biological markers. Studies evaluated the effects of combining the drug with standard physical therapy on mobility assessments.

The evidence remains limited regarding the long-term impact on disease progression; most current studies are focused on symptom management over a six-month duration.

Safety and Patient Profile

Research has examined the drug's profile in individuals with a history of heart issues. Trials monitored for specific adverse events, including changes in heart rhythm and blood pressure.

Studies evaluated the drug's activity regarding pain and sleep quality. Research has also been conducted to compare the drug with other treatments regarding incidence of side effects. Research findings regarding specific side effects, such as dizziness and nausea, were recorded across all phase II and III trials.

Overall, the collected evidence describes the drug's profile as evaluated in research studies. Ongoing research continues to investigate long-term safety data.

Frequently Asked Questions (FAQ)

Common questions about Anaesthesin (FAQ)

Q: How quickly does Anaesthesin usually start working?

A: Official drug literature indicates that the onset of the localized numbing effect can occur rapidly, often within a minute or less of applying the product to the affected area. This quick action is due to the way the medication works directly at the sensory nerve endings.

Q: How long does the numbing effect of Anaesthesin last?

A: The localized numbing effect is typically described in official information as being short in duration. The duration of action often lasts from a few minutes up to 15 to 20 minutes. The limited duration of effect is why product labeling specifies frequency ceilings for repeat use.

Q: Can Anaesthesin be used for mouth pain?

A: Yes, products containing Anaesthesin are officially indicated for the temporary relief of minor pain and irritation in the mouth and throat. This includes discomfort from conditions such as a sore throat or mouth ulcers, as defined by regulatory documents.

Q: Is Anaesthesin used to treat itching?

A: Official product labeling for topical forms of Anaesthesin describes its use for the temporary relief of both pain and itching. This application covers discomfort associated with minor skin irritations or other specific localized conditions.

Q: Is Anaesthesin considered an over-the-counter medicine in some places?

A: In many jurisdictions, some products containing Anaesthesin are classified as over-the-counter (OTC) medicines intended for non-prescription use by patients. However, the regulatory classification can vary based on the concentration and the specific product formulation.

Q: Can Anaesthesin be used on open cuts or wounds?

A: Official guidance includes cautions against using Anaesthesin on large areas of the body or on broken, raw, or damaged skin. This caution is included because applying the product to damaged skin is associated with a greater potential for the drug to be absorbed into the body.

Q: Does Anaesthesin cause any kind of tingling feeling?

A: Some patients may experience a temporary, mild burning, stinging, or irritation sensation when the product is first applied. While official documents do not typically describe a 'tingling' feeling specifically, a brief local reaction upon application is a commonly reported experience.

Q: What happens if Anaesthesin is swallowed?

A: Official warnings strongly caution against swallowing Anaesthesin products, especially by children. Regulatory warnings indicate that if large amounts are ingested, consultation with a healthcare professional is necessary due to the potential for systemic absorption and serious side effects.

Q: Is Anaesthesin safe to use during pregnancy according to official sources?

A: Official product information notes that human pregnancy data are lacking. Use during pregnancy is a matter for individualized medical consideration, as described in official guidance, and should be discussed with a healthcare provider.

Q: Are there any specific medical conditions that mean someone should not use Anaesthesin?

A: Regulatory documents list specific contraindications for use. These include a known allergy to the drug or certain inherited blood disorders, such as methemoglobinemia, that are associated with an increased risk of serious complications.

Q: Can Anaesthesin interact with heart or blood pressure medications?

A: Due to the potential for systemic absorption, official warnings advise caution for patients with severe heart disease or certain other serious conditions. These individuals may be at a higher risk for complications if the drug is absorbed into the bloodstream.

Q: What are the signs of having a bad reaction to Anaesthesin?

A: Signs of a serious reaction described in official documents include developing pale, gray, or blue-colored skin, lips, or nail beds. These may be signs of a serious, rare blood disorder called methemoglobinemia, or other complications.

Q: Is a slight burning feeling normal when applying Anaesthesin?

A: Yes, a temporary, mild burning, stinging, or irritation at the application site is listed in official documents as a common sensation when using the product. This effect should be mild and resolve quickly.

Q: What is the risk of a serious side effect called methemoglobinemia with Anaesthesin?

A: Official drug warnings specify that Anaesthesin is associated with methemoglobinemia, a rare but serious blood disorder that reduces the blood’s ability to carry oxygen. The risk is elevated in certain populations, including infants, the elderly, and individuals with underlying conditions.

Q: Is there any research on long-term effects of using Anaesthesin frequently?

A: Official regulatory instructions consistently limit the duration of use to a short period, typically seven days or less. This short duration of use is recommended to help minimize any theoretical risks associated with frequent or prolonged systemic exposure.

Q: What does official guidance say about using Anaesthesin on large areas of skin?

A: Official guidance cautions against using the product on large areas of skin. This is a risk mitigation strategy, as covering a large surface area increases the amount of drug that may be absorbed into the body, leading to higher systemic exposure.

Q: Why might Anaesthesin not work for some people?

A: The mechanism of action for Anaesthesin is known to be affected by the local tissue pH. Official documents suggest that in more acidic environments, such as heavily inflamed or infected tissue, the drug’s effectiveness in blocking nerve signals may be reduced.

Q: Does using Anaesthesin make the skin more sensitive to the sun?

A: Official product information includes a warning that using Anaesthesin may increase skin sensitivity to sunlight, a condition known as photosensitivity. Official guidance mentions that protective measures, such as covering the area, may be useful after application.

Q: Can I use Anaesthesin if I have a known allergy to other local anesthetics?

A: Official warnings state that Anaesthesin (an ester-type anesthetic) may cause an allergic reaction in individuals who are known to be sensitive to other ester-type local anesthetics. This cross-sensitivity is a known risk described in regulatory literature.

Q: Are there any official warnings about using Anaesthesin in infants?

A: Regulatory agencies have issued strong warnings and contraindications against the use of oral Anaesthesin products in children under two years of age. This is due to the significantly heightened risk of serious adverse effects like methemoglobinemia in this population.

Q: What is the difference between an anesthetic and an analgesic?

A: Official descriptions explain that an anesthetic temporarily causes a loss of sensation, including pain, in a localized area where it is applied. In contrast, an analgesic relieves pain without causing a complete loss of feeling.

Q: Do studies support the use of Anaesthesin for sore throats?

A: Yes, official product indications confirm that Anaesthesin is used for the temporary relief of minor pain, including that associated with sore throats. This is a common and approved use described in regulatory documents.

Q: Is it possible to become dependent on Anaesthesin for pain relief?

A: Regulatory guidance emphasizes that the product is for short-term, temporary use only. It is not intended for chronic use or long-term pain management. The required short-term use supports the role of the product for temporary relief, not chronic pain management.

Q: Does Anaesthesin have any impact on driving or operating machinery?

A: While it is a local treatment, regulatory documents that list potential systemic side effects include symptoms such as dizziness or lightheadedness, which may occur in rare instances of high absorption. Caution is warranted if these effects are experienced.

Q: What are the ingredients in Anaesthesin products besides the active drug?

A: Official regulatory documents, such as DailyMed monographs, list all inactive ingredients, or excipients, used in the final product formulation. These ingredients vary by the specific product type, such as lozenge, cream, or spray.

Q: Is Anaesthesin used in dental procedures?

A: Yes, Anaesthesin-containing products are commonly used in dental settings as a topical anesthetic. It is applied to the oral mucosa to numb a localized area before certain procedures.

Q: What are the official sources for safety information regarding Anaesthesin?

A: Authoritative sources for safety information include regulatory body websites and published documents. Examples are the FDA’s DailyMed monographs, NIH’s MedlinePlus patient information, and advisories from international bodies like Health Canada and the EMA.

Q: Are there any documented cases of overdose with topical Anaesthesin products?

A: Official regulatory communications discuss cases of over-exposure, particularly related to the systemic effects of the drug. These cases primarily involve misuse or excessive application, often leading to the serious side effect methemoglobinemia.

Q: Why are people with G6PD deficiency sometimes warned about Anaesthesin?

A: Official warnings specify that individuals with the inherited condition Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are at an increased risk of developing methemoglobinemia if they use Anaesthesin. This is a crucial safety caution noted in regulatory literature.

Q: What is the recommended period of time to use Anaesthesin before seeing a doctor?

A: Official instructions typically state that if the condition for which the product is being used does not improve within seven days, or if it worsens, use should be stopped. The purpose of this limit is to ensure that a healthcare professional evaluates persistent symptoms.

Q: Can using too much Anaesthesin hide symptoms of a more serious problem?

A: Official product information includes a caution that if symptoms do not improve, or if the underlying condition is severe, continued use of the drug may mask symptoms of a more serious, untreated medical problem. The guidance on short-term use supports this caution.

Q: Can a person be allergic to Anaesthesin?

A: Yes, official warnings state that Anaesthesin can cause allergic reactions. These reactions may manifest as hives, itching, swelling, or blistering. If these signs are observed, official warnings advise stopping use immediately.

Q: What are the restrictions on Anaesthesin use in older adults?

A: Official safety warnings indicate that older adult patients may be at an increased risk of developing the serious side effect methemoglobinemia. The increased risk for this population is the basis for careful consideration of the dose and frequency.

Q: Is there a documented 'maximum dose' for Anaesthesin in adults?

A: Official instructions for use specify strict limits on the concentration, frequency, and amount applied to the affected area. These limits are in place to prevent exceeding the documented thresholds for systemic absorption and to minimize side effect risks.

Q: What are the storage guidelines for Anaesthesin products?

A: Official patient instructions typically advise storing the product in a closed container at room temperature, away from excessive heat, moisture, and direct light. All products should be stored strictly out of the reach of children.

Q: Why do some official documents mention using the lowest effective dose of Anaesthesin?

A: The official guidance to use the lowest effective dose is a fundamental risk mitigation strategy. It is aimed at minimizing the amount of drug absorbed into the bloodstream, which ultimately reduces the potential for serious systemic side effects.

How should Anaesthesin be stored and disposed of?

Anaesthesin (Benzocaine) must be stored and handled according to the specific requirements detailed on its official regulatory label.


Storage and Handling Requirements

Category Requirement
Temperature Store at controlled room temperature, typically 59 –86 F (15 –30 C), and protect from freezing.
Protection Keep the container tightly closed, away from heat, moisture, and direct light.
Child Safety Keep out of the reach of children.
Aerosols Preserve in pressurized containers and avoid excessive heat.

Disposal Instructions

Unused or expired Anaesthesin must be disposed of in accordance with local regulations.

Pressurized aerosol containers must not be punctured or incinerated.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anaesthesin found in:

A-Z Index: